In addition to obesity therapies, the other potential use of MC4R agonists as therapeutics for erectile dysfunction and premenopausal hypoactivity sexual desire disorder has also been investigated, including melanotan II (University of Arizona) [225], bremelanotide (Palatin Inc) [226], and PF-00446687 (Pfizer Inc) [227]. This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.